etidronate has been researched along with Disease Models, Animal in 77 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Icariin (ICA), one of the main flavonoids from plants of the Epimedium genus, has been shown to ameliorate osteoporosis and improve bone health in preclinical studies." | 8.02 | Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis. ( Ha, TTM; Lai, TT; Nguyen, HVM; Pham, CV; Pham, TT; Phuong, TT; To, TT; Tran, LD; Trinh, DC; Winkler, C, 2021) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 5.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| " Icariin (ICA), one of the main flavonoids from plants of the Epimedium genus, has been shown to ameliorate osteoporosis and improve bone health in preclinical studies." | 4.02 | Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis. ( Ha, TTM; Lai, TT; Nguyen, HVM; Pham, CV; Pham, TT; Phuong, TT; To, TT; Tran, LD; Trinh, DC; Winkler, C, 2021) |
| "Cows fed a balanced diet with the required amounts of calcium and phosphorus developed acute hypocalcemia and hypophosphatemia shortly after parturition, even in the presence of the a responsive parathyroid gland, when bone resorption was selectively inhibited by the prepartal administration of disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP)." | 3.65 | Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resportion. ( Black, HE; Capen, CC; Geho, WB; Potts, JT; Re, R; Yarrington, JT, 1976) |
| "Pseudoxanthoma elasticum is a prototype of heritable ectopic mineralization disorders, with phenotypic overlap with generalized arterial calcification of infancy and arterial calcification due to CD73 deficiency." | 2.55 | Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016. ( Li, Q; Terry, SF; Uitto, J; van de Wetering, K; Váradi, A, 2017) |
| "Vascular dementia is a neurodegenerative disorder caused by the reduction of cerebral blood flow." | 1.46 | Etidronate rescues cognitive deficits through improving synaptic transmission and suppressing apoptosis in 2-vessel occlusion model rats. ( Cheong, YK; Li, W; Ren, G; Yang, Z; Yu, Y; Yuan, H, 2017) |
| " Considering low bioavailability of bisphosphonates when administered orally, subsequent studies tested the mice with subcutaneous injections of etidronate." | 1.43 | Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy. ( Kingman, J; Levine, MA; Li, Q; Sundberg, JP; Uitto, J, 2016) |
| "Treatment with etidronate had no effect on bone parameters in the WT mice; however, the Enpp1-/- mice displayed an increased structural model index (SMI; P<0." | 1.42 | Effects of etidronate on the Enpp1⁻/⁻ mouse model of generalized arterial calcification of infancy. ( Huesa, C; MacRae, VE; Millán, JL; Staines, KA, 2015) |
| "Alendronate treatment reduced bony osteophyte development." | 1.36 | In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. ( Doschak, MR; Jones, MD; Li, G; Maksymowych, WP; Tran, CW; Zernicke, RF, 2010) |
| "Otosclerosis is a bony dyscrasia characterized by histopathological findings of osteoclast production." | 1.35 | Medical treatment of otosclerosis: rationale for use of bisphosphonates. ( Brookler, K, 2008) |
| " In two groups, anterior cruciate ligament transection was performed and half were left untreated, and the other half dosed with risedronate (0." | 1.35 | Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy. ( Boyd, SK; Doschak, MR; MacNeil, JA; Zernicke, RF, 2008) |
| "Osteoporosis is a severe complication of glucocorticoid treatment." | 1.34 | Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. ( Bertoldo, F; Dalle Carbonare, L; Fassina, A; Giannini, S; Lo Cascio, V; Realdi, G; Sella, S; Turco, G; Valenti, MT; Zordan, S, 2007) |
| " Our data show that ED at a dosage that suppresses bone metabolism markedly inhibits vascular calcification in rats with renal failure." | 1.33 | Effect of etidronate on aortic calcification and bone metabolism in calcitriol-treated rats with subtotal nephrectomy. ( Aizawa, S; Hashiba, H; Kogo, H; Suzuki, Y; Tamura, H; Tamura, K, 2005) |
| "The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether post-surgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis." | 1.33 | Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. ( Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006) |
| "The purpose of the present study was to examine the effect of pretreatment with risedronate and/or vitamin K2 and treatment continuation with reduced dosing frequency of the drugs on the early cancellous bone loss induced by ovariectomy (OVX) in rats." | 1.33 | Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study. ( Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006) |
| "A murine model of acute Chagas' disease was used, in which experimental animals were infected with 10(3) trypomastigotes and intravenous treatment was started 24 h post-infection." | 1.32 | Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. ( Baptista, MM; Britto, CC; de Castro, SL; Docampo, R; Garzoni, LR; Meirelles, Mde N; Oldfield, E; Urbina, JA; Waghabi, MC, 2004) |
| " The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat." | 1.31 | Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. ( Hunziker, J; Miller, SC; Wronski, TJ, 2000) |
| " Since ISA-13 is well absorbed through mucose tissues, we suggest that ISA-13 efficacy on reducing bone loss should be tested by its application on the mucosal tissue." | 1.31 | The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model. ( Binderman, I; Breuer, E; Golomb, G; Yaffe, A, 2000) |
| "When the inhibition of bone resorption by calcitonin, osteoprotegerin, or alendronate is combined with the acute inhibition of bone mineralization with etidronate, the BRC model correctly predicts that there will no longer be a sharp rise in calcium and phosphate, and, therefore, there will no longer be the formation of the fetuin-mineral complex." | 1.31 | Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. ( Caputo, JM; Price, PA; Williamson, MK, 2002) |
| "Etidronate treatment of 5 mg/kg, 5 days/week was administered for 2 weeks and exercised on a treadmill for 30 m/min, 60 min/day, 5 days/week for 10 weeks." | 1.30 | Effects of exercise training and etidronate treatment on bone mineral density and trabecular bone in ovariectomized rats. ( Akamine, T; Goshi, N; Kurata, H; Sakou, T; Tamaki, H, 1998) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 1.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| " L-T4 treatment resulted in reduction in BMDs in the lumbar spine, tail, and femur as measured by dual energy X-ray absorptiometry, but there was no correlation with the dosage of L-T4 or the serum T4 level." | 1.29 | A rat model of thyroid hormone-induced bone loss: effect of antiresorptive agents on regional bone density and osteocalcin gene expression. ( Kung, AW; Ng, F, 1994) |
| "The present study was undertaken to test whether long term administration of HEBP could prevent the progress of bone loss induced by ovariectomy in rats." | 1.28 | Effect of HEBP (1-hydroxyethylidene-1,1-bisphosphonate) on experimental osteoporosis induced by ovariectomy in rats. ( Arai, M; Hironaka, M; Matsumoto, S; Shinoda, H; Togari, A, 1991) |
| "The rat adjuvant arthritis model, like human rheumatoid arthritis, is characterized by fulminating intra- and periarticular inflammation and bone lysis." | 1.28 | NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. ( Boyce, RW; Francis, MD; Hovancik, K, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (12.99) | 18.7374 |
| 1990's | 25 (32.47) | 18.2507 |
| 2000's | 26 (33.77) | 29.6817 |
| 2010's | 15 (19.48) | 24.3611 |
| 2020's | 1 (1.30) | 2.80 |
| Authors | Studies |
|---|---|
| Pham, CV | 1 |
| Pham, TT | 1 |
| Lai, TT | 1 |
| Trinh, DC | 1 |
| Nguyen, HVM | 1 |
| Ha, TTM | 1 |
| Phuong, TT | 1 |
| Tran, LD | 1 |
| Winkler, C | 1 |
| To, TT | 1 |
| Uitto, J | 2 |
| Li, Q | 2 |
| van de Wetering, K | 2 |
| Váradi, A | 2 |
| Terry, SF | 1 |
| Pomozi, V | 1 |
| Brampton, C | 1 |
| Zoll, J | 1 |
| Calio, B | 1 |
| Pham, K | 1 |
| Owens, JB | 1 |
| Marh, J | 1 |
| Moisyadi, S | 1 |
| Martin, L | 1 |
| Bauer, C | 1 |
| Erdmann, J | 1 |
| Aherrahrou, Z | 1 |
| Le Saux, O | 1 |
| Von Schacht, E | 1 |
| Dambacher, MA | 1 |
| Ringe, JD | 1 |
| Dukas, L | 1 |
| Thomsen, JS | 2 |
| Straarup, TS | 1 |
| Danielsen, CC | 2 |
| Oxlund, H | 1 |
| Brüel, A | 1 |
| Sahana, H | 1 |
| Khajuria, DK | 1 |
| Razdan, R | 1 |
| Mahapatra, DR | 1 |
| Bhat, MR | 1 |
| Suresh, S | 1 |
| Rao, RR | 1 |
| Mariappan, L | 1 |
| Wei, YJ | 1 |
| Wang, CM | 1 |
| Cai, XT | 1 |
| Zhan, Y | 1 |
| Jia, XB | 1 |
| Kikuta, J | 1 |
| Ishii, M | 1 |
| Huesa, C | 1 |
| Staines, KA | 1 |
| Millán, JL | 1 |
| MacRae, VE | 1 |
| Kingman, J | 1 |
| Sundberg, JP | 1 |
| Levine, MA | 1 |
| Li, W | 1 |
| Yuan, H | 1 |
| Yu, Y | 1 |
| Cheong, YK | 1 |
| Ren, G | 1 |
| Yang, Z | 1 |
| Iwamoto, J | 4 |
| Matsumoto, H | 1 |
| Takeda, T | 4 |
| Sato, Y | 4 |
| Liu, X | 1 |
| Yeh, JK | 4 |
| Lawson, MA | 1 |
| Coulton, L | 1 |
| Ebetino, FH | 1 |
| Vanderkerken, K | 1 |
| Croucher, PI | 1 |
| Yokote, Y | 1 |
| Kimura, E | 1 |
| Kimura, M | 1 |
| Kozono, Y | 1 |
| Brookler, K | 1 |
| Wang, X | 1 |
| Erickson, AM | 1 |
| Allen, MR | 1 |
| Burr, DB | 2 |
| Martin, RB | 1 |
| Hazelwood, SJ | 1 |
| Shiraishi, A | 1 |
| Miyabe, S | 1 |
| Nakano, T | 1 |
| Umakoshi, Y | 1 |
| Ito, M | 1 |
| Mihara, M | 1 |
| Liepe, K | 1 |
| Geidel, HH | 1 |
| Bergmann, R | 1 |
| Haase, M | 1 |
| Runge, R | 1 |
| Kotzerke, J | 1 |
| Jones, MD | 1 |
| Tran, CW | 1 |
| Li, G | 1 |
| Maksymowych, WP | 1 |
| Zernicke, RF | 2 |
| Doschak, MR | 2 |
| Heidari, P | 1 |
| Abbaspour, A | 1 |
| Baghdadi, T | 1 |
| Espandar, R | 1 |
| Farzan, M | 1 |
| Amanpour, S | 1 |
| Rasouli, MR | 1 |
| Mohagheghi, MA | 1 |
| Amiri, HR | 1 |
| Yasui, N | 1 |
| Orita, S | 1 |
| Ohtori, S | 1 |
| Koshi, T | 1 |
| Yamashita, M | 1 |
| Yamauchi, K | 1 |
| Inoue, G | 1 |
| Suzuki, M | 1 |
| Eguchi, Y | 1 |
| Kamoda, H | 1 |
| Arai, G | 1 |
| Ishikawa, T | 1 |
| Miyagi, M | 1 |
| Ochiai, N | 1 |
| Kishida, S | 1 |
| Takaso, M | 1 |
| Aoki, Y | 1 |
| Toyone, T | 1 |
| Takahashi, K | 1 |
| Geoffroy, V | 1 |
| Paschalis, EP | 1 |
| Libouban, H | 2 |
| Blouin, S | 1 |
| Ostertag, A | 1 |
| Chappard, D | 2 |
| Cros, M | 1 |
| Phipps, R | 1 |
| de Vernejoul, MC | 1 |
| Kim, S | 1 |
| Seiryu, M | 1 |
| Okada, S | 1 |
| Kuroishi, T | 1 |
| Takano-Yamamoto, T | 1 |
| Sugawara, S | 1 |
| Endo, Y | 1 |
| Matsubara, M | 1 |
| Nakamura, K | 1 |
| Morita, S | 1 |
| Kashima, I | 1 |
| Grases, F | 1 |
| Perelló, J | 1 |
| Prieto, RM | 1 |
| Simonet, BM | 1 |
| Torres, JJ | 1 |
| Garzoni, LR | 1 |
| Waghabi, MC | 1 |
| Baptista, MM | 1 |
| de Castro, SL | 1 |
| Meirelles, Mde N | 1 |
| Britto, CC | 1 |
| Docampo, R | 1 |
| Oldfield, E | 1 |
| Urbina, JA | 1 |
| Yamamoto, K | 1 |
| Imakiire, A | 1 |
| Shishido, T | 1 |
| Masaoka, T | 1 |
| Shimshi, M | 1 |
| Abe, E | 1 |
| Fisher, EA | 1 |
| Zaidi, M | 1 |
| Fallon, JT | 1 |
| Bouzahzah, B | 1 |
| Jelicks, LA | 1 |
| Morris, SA | 1 |
| Weiss, LM | 1 |
| Tanowitz, HB | 1 |
| Tamura, K | 2 |
| Suzuki, Y | 2 |
| Hashiba, H | 1 |
| Tamura, H | 1 |
| Aizawa, S | 2 |
| Kogo, H | 2 |
| Wakchoure, S | 1 |
| Merrell, MA | 1 |
| Aldrich, W | 1 |
| Millender-Swain, T | 1 |
| Harris, KW | 1 |
| Triozzi, P | 1 |
| Selander, KS | 1 |
| Carvalho, AP | 1 |
| Bezerra, MM | 1 |
| Girão, VC | 1 |
| Cunha, FQ | 1 |
| Rocha, FA | 1 |
| Seki, A | 1 |
| Yamada, H | 1 |
| Shen, CL | 2 |
| Matsushita, M | 1 |
| Fujii, H | 1 |
| Miyaura, C | 1 |
| Dalle Carbonare, L | 1 |
| Bertoldo, F | 1 |
| Valenti, MT | 1 |
| Zordan, S | 1 |
| Sella, S | 1 |
| Fassina, A | 1 |
| Turco, G | 1 |
| Realdi, G | 1 |
| Lo Cascio, V | 1 |
| Giannini, S | 1 |
| MacNeil, JA | 1 |
| Boyd, SK | 1 |
| McClure, J | 1 |
| Morio, Y | 1 |
| Katsumata, T | 1 |
| Nakamura, T | 1 |
| Ohnishi, H | 1 |
| Sakurama, T | 1 |
| Qi, H | 2 |
| Li, M | 2 |
| Wronski, TJ | 8 |
| Jee, WS | 3 |
| Lin, BY | 1 |
| Ma, YF | 2 |
| Ke, HZ | 2 |
| Mosekilde, L | 2 |
| Søgaard, CH | 2 |
| Boyce, RW | 2 |
| Ebert, DC | 1 |
| Stevens, ML | 1 |
| Paddock, CL | 1 |
| Youngs, TA | 1 |
| Gundersen, HJ | 1 |
| McOsker, JE | 2 |
| Azuma, Y | 1 |
| Sato, H | 1 |
| Oue, Y | 1 |
| Okabe, K | 1 |
| Ohta, T | 1 |
| Tsuchimoto, M | 1 |
| Kiyoki, M | 1 |
| Baumann, BD | 1 |
| Alatli-Kut, I | 1 |
| Hultenby, K | 1 |
| Hammarström, L | 1 |
| Kung, AW | 1 |
| Ng, F | 1 |
| Dann, LM | 2 |
| Yen, CF | 1 |
| Rodan, GA | 1 |
| Seedor, JG | 1 |
| Balena, R | 1 |
| Hirsch, D | 1 |
| Drader, J | 1 |
| Pathak, YV | 1 |
| Yee, R | 1 |
| Schoen, FJ | 2 |
| Levy, RJ | 3 |
| Liang, HH | 1 |
| Pan, Z | 1 |
| Setterberg, RB | 1 |
| Li, XJ | 2 |
| Megdiatov, RS | 1 |
| Vorobeĭchik, IaM | 1 |
| Dolgikh, VG | 1 |
| Reshetniak, VK | 1 |
| Ma, Y | 1 |
| Chen, Y | 1 |
| Gasser, J | 1 |
| Kimmel, DB | 1 |
| Wojtowicz, N | 1 |
| Kamiński, A | 1 |
| Sotowski, R | 1 |
| Dziedzic-Gocławska, N | 1 |
| Stachowicz, W | 1 |
| Lepola, VT | 1 |
| Kippo, K | 1 |
| Hannuniemi, R | 1 |
| Laurén, L | 1 |
| Virtamo, T | 1 |
| Osterman, T | 1 |
| Jalovaara, P | 1 |
| Sellman, R | 1 |
| Väänänen, HK | 1 |
| Tamaki, H | 1 |
| Akamine, T | 1 |
| Goshi, N | 1 |
| Kurata, H | 1 |
| Sakou, T | 1 |
| Li, QN | 1 |
| Liang, NC | 1 |
| Huang, LF | 1 |
| Wu, T | 1 |
| Hu, B | 1 |
| Mo, LE | 1 |
| Henge-Napoli, MH | 1 |
| Ansoborlo, E | 1 |
| Chazel, V | 1 |
| Houpert, P | 1 |
| Paquet, F | 1 |
| Gourmelon, P | 1 |
| Hunziker, J | 1 |
| Miller, SC | 1 |
| Yaffe, A | 1 |
| Golomb, G | 1 |
| Breuer, E | 1 |
| Binderman, I | 1 |
| Mashiba, T | 1 |
| Turner, CH | 1 |
| Hirano, T | 1 |
| Forwood, MR | 1 |
| Jacob, DS | 1 |
| Johnston, CC | 1 |
| Moreau, MF | 1 |
| Legrand, E | 1 |
| Baslé, MF | 1 |
| Audran, M | 1 |
| Price, PA | 1 |
| Caputo, JM | 1 |
| Williamson, MK | 1 |
| Flora, L | 1 |
| Doyle, DV | 1 |
| Dunn, CJ | 1 |
| Willoughby, DA | 1 |
| Yarrington, JT | 1 |
| Capen, CC | 1 |
| Black, HE | 1 |
| Re, R | 1 |
| Potts, JT | 1 |
| Geho, WB | 1 |
| Lien, J | 1 |
| Kaye, M | 1 |
| Togari, A | 1 |
| Arai, M | 1 |
| Hironaka, M | 1 |
| Matsumoto, S | 1 |
| Shinoda, H | 1 |
| Shevrin, DH | 1 |
| Gorny, KI | 1 |
| Rosol, TJ | 1 |
| Kukreja, SC | 1 |
| Scott, KS | 1 |
| Crooke, LR | 1 |
| Francis, MD | 1 |
| Hovancik, K | 1 |
| Webb, CL | 1 |
| Benedict, JJ | 1 |
| Linden, JA | 1 |
| Guaitani, A | 1 |
| Sabatini, M | 1 |
| Coccioli, G | 1 |
| Cristina, S | 1 |
| Garattini, S | 1 |
| Bartosek, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)[NCT03813550] | 20 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for etidronate and Disease Models, Animal
| Article | Year |
|---|---|
Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016.
Topics: 5'-Nucleotidase; Alkaline Phosphatase; Animals; Biopsy, Needle; Clinical Trials as Topic; Congresses | 2017 |
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactio | 2012 |
[Dynamics of bone resorption analyzed by intravital imaging].
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; | 2013 |
Preclinical pharmacology of alendronate.
Topics: Alendronate; Animals; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Estrogens; | 1993 |
[Pathogenesis and prevention of calcinosis of bioprostheses].
Topics: Animals; Bioprosthesis; Calcinosis; Disease Models, Animal; Etidronic Acid; Heart Valve Prosthesis; | 1991 |
72 other studies available for etidronate and Disease Models, Animal
| Article | Year |
|---|---|
Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Disease Models, Animal; Etidronic Acid; Fish | 2021 |
Pyrophosphate Supplementation Prevents Chronic and Acute Calcification in ABCC6-Deficient Mice.
Topics: Acute Disease; Animals; ATP-Binding Cassette Transporters; Calcinosis; Chronic Disease; Diphosphates | 2017 |
No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Cartilage, A | 2013 |
Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis.
Topics: Adsorption; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Chemistry, Pharmaceutica | 2013 |
[Establishment of zebrafish osteopenia model induced by dexamethasone].
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcification, Ph | 2013 |
Effects of etidronate on the Enpp1⁻/⁻ mouse model of generalized arterial calcification of infancy.
Topics: Animals; Aorta; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Disease | 2015 |
Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy.
Topics: Animals; Animals, Newborn; Biopsy, Needle; Bone and Bones; Choristoma; Diphosphonates; Disease Model | 2016 |
Etidronate rescues cognitive deficits through improving synaptic transmission and suppressing apoptosis in 2-vessel occlusion model rats.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cerebrovascular Disorders; Cognition Disorders | 2017 |
Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Dru | 2008 |
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Count; Diphosphonates; Disease Model | 2008 |
Biomechanical analysis of combined treatment of high calcium and bisphosphonate in tibia of steroid-treated growing-phase rats.
Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Ag | 2008 |
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined | 2008 |
Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.
Topics: Alendronate; Animals; Computer Simulation; Disease Models, Animal; Dogs; Etidronic Acid; Fractures, | 2009 |
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
Topics: Animals; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Diseas | 2009 |
Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
Topics: Animals; Autoradiography; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; | 2009 |
In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.
Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Dis | 2010 |
Effect of risedronate on bone resorption during consolidation phase of distraction osteogenesis: a rabbit model.
Topics: Animals; Bone Density Conservation Agents; Bone Regeneration; Bone Resorption; Disease Models, Anima | 2010 |
The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation.
Topics: Afferent Pathways; Animals; Back Pain; Bone Density Conservation Agents; Cells, Cultured; Disease Mo | 2010 |
Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Core Binding Factor Alph | 2011 |
Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of anti-resorptive effects on bone.
Topics: Acetic Acid; Analgesics; Animals; Capsaicin; Clodronic Acid; Corticosterone; Diphosphonates; Disease | 2013 |
Non-invasive assessment of bone quality.
Topics: Aged; Aged, 80 and over; Animals; Bone and Bones; Bone Density; Cadaver; Disease Models, Animal; Ela | 1999 |
Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats.
Topics: Administration, Oral; Animals; Calcinosis; Diet; Disease Models, Animal; Etidronic Acid; Injections, | 2004 |
Antiparasitic activity of risedronate in a murine model of acute Chagas' disease.
Topics: Acute Disease; Alkyl and Aryl Transferases; Animals; Chagas Disease; Disease Models, Animal; Enzyme | 2004 |
Effects of ethane-1-hydroxy-1,1-diphosphonate on ossification of the posterior longitudinal ligament in Zucker fatty rats.
Topics: Animals; Biopsy, Needle; Disease Models, Animal; Etidronic Acid; Female; Immunohistochemistry; Male; | 2004 |
Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice.
Topics: Alendronate; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Carotid Stenosis; Diphosphonates; | 2005 |
Risedronate in the treatment of Murine Chagas' disease.
Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Disease Models, Animal; Etidronic Acid; Mice; Mice, | 2005 |
Effect of etidronate on aortic calcification and bone metabolism in calcitriol-treated rats with subtotal nephrectomy.
Topics: Amino Acids; Animals; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Body Weight; Bone and Bone | 2005 |
Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.
Topics: Animals; Cell Division; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Etidronic Acid; Im | 2006 |
Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Diphosphonates; | 2006 |
Therapeutic effect of risedronate on cancellous and cortical bone in ovariectomized osteopenic rats: a comparison with the effects of alfacalcidol.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Models, | 2006 |
Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Meta | 2006 |
Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conse | 2006 |
Prevention of aortic calcification by etidronate in the renal failure rat model.
Topics: Animals; Aortic Diseases; Bone Density; Calcinosis; Calcium; Calcium-Binding Proteins; Disease Model | 2007 |
Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Mo | 2007 |
Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Computer Simulation; Disease Models, Ani | 2008 |
The effects of disodium ethane-hydroxy-1,1-diphosphonate and disodium dichloromethylene diphosphonate on lanthanide-induced calcergy.
Topics: Animals; Calcinosis; Clodronic Acid; Diphosphonates; Disease Models, Animal; Etidronic Acid; Hydroca | 1982 |
[Congenital angular deformity of the tibia in chick embryo induced by ethane-1-hydroxy-1, 1-diphosphonate (EHDP)].
Topics: Abnormalities, Drug-Induced; Animals; Chick Embryo; Disease Models, Animal; Etidronic Acid; Radiogra | 1984 |
Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats.
Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Biomechanical Phenomena; Blood Chemical Analy | 1995 |
A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats.
Topics: Aging; Animals; Biomarkers; Bone Development; Bone Diseases, Metabolic; Bone Remodeling; Calcitonin; | 1995 |
Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcium Channe | 1995 |
Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitoni | 1995 |
Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Disease Models, Animal; Estradiol; Etidronic Aci | 1995 |
The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model.
Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone | 1995 |
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotope | 1995 |
Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats.
Topics: Animals; Biomarkers; Bone Density; Bone Development; Bone Resorption; Calcitonin; Disease Models, An | 1995 |
Disturbances of cementum formation induced by single injection of 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) in rats: light and scanning electron microscopic studies.
Topics: Animals; Dental Cementum; Dental Enamel; Dentin; Disease Models, Animal; Etidronic Acid; Hyperplasia | 1994 |
A rat model of thyroid hormone-induced bone loss: effect of antiresorptive agents on regional bone density and osteocalcin gene expression.
Topics: Animals; Base Sequence; Bone Density; Bone Resorption; Calcitonin; Disease Models, Animal; DNA, Comp | 1994 |
Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Disease Models, Animal; Estradiol; Etidronic Acid | 1993 |
Synergistic inhibition of the calcification of glutaraldehyde pretreated bovine pericardium in a rat subdermal model by FeCl3 and ethanehydroxydiphosphonate: preincubation and polymeric controlled release studies.
Topics: Animals; Bioprosthesis; Calcinosis; Cattle; Chlorides; Delayed-Action Preparations; Disease Models, | 1993 |
Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats.
Topics: Analysis of Variance; Animals; Bone Diseases, Metabolic; Dinoprostone; Disease Models, Animal; Drug | 1995 |
[The role of zinc ions in the pathogenesis of trigeminal neuralgia (experimental and clinical research)].
Topics: Aged; Animals; Brain; Brain Chemistry; Chelating Agents; Diphosphonates; Disease Models, Animal; Dru | 1995 |
Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Disease Models, Animal | 1995 |
[Effect of bisphosphonates (HEBP, CL2MBP) on the process of biological mineralization in fresh bone and bone tissue de novo as a result of experimental osteogenesis induction in guinea pigs].
Topics: Animals; Bone Transplantation; Calcification, Physiologic; Clodronic Acid; Disease Models, Animal; E | 1995 |
Bisphosphonates clodronate and etidronate in the prevention of ovariectomy-induced osteopenia in growing rats.
Topics: Analysis of Variance; Animals; Bone Diseases, Metabolic; Clodronic Acid; Disease Models, Animal; Dos | 1996 |
Effects of exercise training and etidronate treatment on bone mineral density and trabecular bone in ovariectomized rats.
Topics: Absorptiometry, Photon; Animals; Bone Density; Disease Models, Animal; Etidronic Acid; Female; Femur | 1998 |
Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Remodeling; Disease Models, Animal; Drug Administration Schedule; Etid | 1999 |
Efficacy of ethane-1-hydroxy-1,1-bisphosphonate (EHBP) for the decorporation of uranium after intramuscular contamination in rats.
Topics: Animals; Antidotes; Bone and Bones; Chelating Agents; Disease Models, Animal; Etidronic Acid; Inject | 1999 |
Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone.
Topics: Analysis of Variance; Animals; Bone Resorption; Calcitonin; Calcium Channel Blockers; Diphosphonates | 2000 |
The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model.
Topics: Administration, Topical; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Chi-Square Dist | 2000 |
Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Remodeling; Disease Models, Animal | 2001 |
Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone and Bones; Bone Density; Climacteric; Disease Mod | 2001 |
Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment.
Topics: Alendronate; alpha-Fetoproteins; Animals; Bone and Bones; Bone Remodeling; Bone Resorption; Calciton | 2002 |
Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Experimental; Body Weight; Bone and Bones; | 1979 |
Potassium permanganate induced calcergy: a model to study the effects of drugs on hydroxyapatite crystal deposition.
Topics: Animals; Calcinosis; Clodronic Acid; Dexamethasone; Disease Models, Animal; Etidronic Acid; Hydroxya | 1979 |
Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resportion.
Topics: Animals; Antigens; Bone Resorption; Calcium; Calcium, Dietary; Cattle; Cattle Diseases; Cyclic AMP; | 1976 |
Changes in red cell, plasma, inulin, and total water compartments in rat femurs. Comparison of vitamin D deficiency and diphosphonate induced rickets.
Topics: Animals; Disease Models, Animal; Erythrocyte Volume; Etidronic Acid; Extracellular Space; Femur; Inu | 1977 |
Effect of HEBP (1-hydroxyethylidene-1,1-bisphosphonate) on experimental osteoporosis induced by ovariectomy in rats.
Topics: Animals; Body Weight; Calcification, Physiologic; Calcium; Disease Models, Animal; Drug Administrati | 1991 |
Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3.
Topics: Animals; Bone Neoplasms; Calcium; Cell Line; Disease Models, Animal; Etidronic Acid; Injections, Sub | 1991 |
Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Diphosphonates; Disease Models, Animal; Estrogens | 1989 |
NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis.
Topics: Animals; Arthritis; Arthritis, Experimental; Bone Resorption; Disease Models, Animal; Etidronic Acid | 1989 |
Inhibition of bioprosthetic heart valve calcification with aminodiphosphonate covalently bound to residual aldehyde groups.
Topics: Aldehydes; Animals; Aortic Valve Stenosis; Bioprosthesis; Calcinosis; Cattle; Diphosphonates; Diseas | 1988 |
An experimental rat model of local bone cancer invasion and its responsiveness to ethane-1-hydroxy-1,1-bis(phosphonate).
Topics: Animals; Bone and Bones; Bone Neoplasms; Calcium; Carcinoma 256, Walker; Disease Models, Animal; Eti | 1985 |